Home

NEW KWN is Posted!!  Go to KWN Newsletter tab


y reimbursements beginning January 1, 2018, with total cuts rising to as much as $1.5 billi



The Centers for Medicare and Medicaid Services (CMS) is proposing more than $600 million in cuts to laboratory reimbursements beginning January 1, 2018, with total cuts rising to as much as $1.5 billion annually compared to current reimbursement levels by 2020. These cuts are part of a flawed implementation of the Preserving Access to Medicare Act (PAMA) passed in 2014.

Over ten years, the cuts may total as much as $13 billion, which is more than three times the estimate of $3.9 billion Congress originally anticipated.

The impact of cuts to the Clinical Laboratory Fee Schedule (CLFS) will fall disproportionately on nursing homes served by local hospitals, small independent laboratories, and laboratories in physician offices, as well as Medicare-dependent hospitals and community hospitals in rural areas. 



We need the entire laboratory community to take action now! Follow this link for more detailed information and to easily contact your elected representatives.

Having committed the agency to a deeply-flawed data collection process, CMS has now drafted a distorted fee schedule built on questionable data collected from just five percent of the laboratories in the United States. CMS admits that just 1.85 percent of data was collected from laboratories serving rural areas.

Cuts to the CLFS will have a ripple effect through private insurers and other government payors like Medicaid, which use the CLFS to set their own rates. The outpatient laboratory service system in the United States could see a reduction in total annual reimbursements by as much as 25 percent over the next three years.  The result will be a dramatic reduction in available testing and access to laboratory services for patients and clinicians. The cuts will also result in a near elimination of capital investment in the latest technologies needed to improve care.

Congress must act to prevent their constituents from losing access to these critical, life-saving medical services.

Deeply Flawed Approach by CMS

Based on the implementation by CMS, Congress could have called this law the Preventing Access to Medicare Act.  Choices made by the agency throughout this process were designed to lock out entire service sites and limit patient access to appropriate laboratory services. CMS chose to:

  • Define which laboratories would report data in the narrowest possible terms, resulting in 90% of reported data coming from independent laboratories. Hospitals and physician office laboratories provide 44% of Medicare services but represent just 8.5% of the reporting entities. Less than 1 percent of hospitals and physician office laboratories reported data. In 2016, HHS Office of Inspector General predicted 3,500 laboratories would report data, but 55% of that number actually did.
  • Change reporting requirements and deadlines multiple times and then ignore concerns that reported data lacked any verification process, resulting in a data set that includes erroneous data points, dramatic outliers and magnitudes of difference between the calculated mean and median. 
  • Ignore the intent of Congress and publish rates for some highly used codes that will cut actual reimbursement by as much as 40% next year. For those HCPCS codes without a National Limitation Amount (e.g. 80061 Lipid Panel), CMS failed to set a reasonable benchmark for what laboratories are currently being reimbursed, and instead, proposes implementing the full cut in a single year.

The laboratory community has warned CMS and Congress during this entire process that the implementation was improperly managed. The agency's own analysis shows significant numbers of reporting entities don't appear to meet the definition of applicable laboratories. The analysis also show entities that submitted inaccurate data. CMS exhibited a pattern of excluding data that would have increased the weighted median, but included questionable data that lowered the weighted median.

In September 2016, The Department of Health and Human Services Office of Inspector General shared its concern about a lack of data validation. "Absent processes to verify whether applicable labs report their data or to verify the quality of data that labs report, CMS may set inaccurate Medicare payment rates for lab tests. PAMA required CMS to set Medicare payments rates for lab tests by using a market-based approach...If CMS does not have appropriate safeguards to ensure that all applicable labs report complete and accurate data, it may result in new Medicare payment rates that are inaccurate." (OEI-09-16-00100)

It is worth noting that CMS, trying to blunt criticism, performed "simulations" of broader reporting of data and claims that additional reporting would have not made a "significant impact." However, the simulations ignore the fact that unreported data would likely be at higher payment rates, making the simulations entirely useless as a predictor of the actual market. The reported "simulations" are designed to distract Congress and the public from the mistakes the agency made during implementation.

Congress may have anticipated these issues. Within the law, Congress directs the General Accounting Office (GAO) to perform a study of the PAMA implementation that examines payment rates across laboratory settings (including laboratories that furnish low volume services), the response from private payors, the impact on beneficiaries, and whether the data "accurately reflects market prices." Congress should accelerate the timeline for this report.

The wide-ranging impact these cuts will have on the entire healthcare system are too grave to base them on incomplete and unverified data. Congress must seek a delay and direct GAO to study the implementation immediately.

Solution

Through the chairs of the Senate Finance, House Ways and Means and House Energy and Commerce, Congress must communicate to the Administration that these misguided cuts must not be implemented. Delay is critical until CMS can work with stakeholders to demonstrate the agency can properly collect and validate data that accurately reflects the market.



For more information please click here and check out the events page!!



  • Ebola -- More Perspectives and Information from CBS, New York Times, and BBC http://www.cbsnews.com/videos/liberian-nurses-follow-strict-protocols-in-treatment-of-ebola-patients/******************************************************************************************************************Gives you a first hand view of the Liberian situation through the eyes of someone ...
    Posted Oct 17, 2014, 11:01 AM by Sally Pestana
  • TODAY Show Interview with Dallas Nurse Interview 10/16/14  --  Nurse who worked with both Ebola patients in Dallas hospital shares her observations and perceptions during interview on the TODAY Show.
    Posted Oct 16, 2014, 12:02 PM by Sally Pestana
  • Do you use a "Fitbit" or "Jawbone"? Physicians Use Fitness Trackers to Monitor Patients in Real-time, Even as Developers Work to Incorporate Medical Laboratory Tests into the Devices                                                                                                                                                                                                                                                                                                                                                             ...
    Posted May 30, 2014, 11:07 PM by Sally Pestana
  • FDA’s Blood Glucose Meter Draft Guidance AACC responds to FDA's recommendations, recommending less stringent requirements for hospital use. Read more here.                                                                                                                                                                                                                                                                                                                                                                                                                 ...
    Posted May 30, 2014, 8:42 PM by Sally Pestana
  • 2014 Award Winners Announced at the Annual Business Meeting! President Clarence Bermejo announced the 2014 ASCLS-HI award winners at the recent ASCLS-HI Annual Business Meeting.   See the complete list of honorees.                                                                                                                                                                                                                                                                                                                                                   ...
    Posted Jun 20, 2014, 12:56 AM by Sally Pestana
  • Enjoy this recent video on how Clark Little got his start shooting waves in Hawaii! ASCLS-HI participates in the ASCLS Annual Meeting Education & Research Silent Auction every year.Several years we've provided a Clark Little photo to the auction. They are always well ...
    Posted May 6, 2014, 1:35 AM by Charles Nguyen
  • Enjoy this very creative portrayal of our profession in this video made by Joanna Ellis, MLS(ASCP) Ms. Ellis is the President of the Texas chapter of ASCLS. Mahalo to her for sharing her creative work!
    Posted May 6, 2014, 1:32 AM by Charles Nguyen
  • 2013 ASCLS Member of the Year Marcia Armstrong was named 2013 ASCLS Member of the Year at the ASCLS 81st Annual Meeting Awards Ceremony in Houston, Texas on Thursday, August 1stShe was selected from twelve ...
    Posted May 6, 2014, 1:29 AM by Charles Nguyen
  • 2014 ASCLS-HI Clinical Laboratory Symposium Update "Changing Tides"October 21 & 22, 2014 Ko’olau Ballroom & Conference CenterNew Meeting Name!New Meeting Month!CLS Planning Committee's goal to meet your CE needs in every way ...
    Posted May 18, 2014, 1:52 PM by Sally Pestana
  • New Website We are very excited to have a new website created by Charles Nguyen
    Posted Mar 6, 2014, 3:33 PM by Charles Nguyen
Showing posts 1 - 10 of 10. View more »



Mission
Voice, Value, Vision
The American Society for Clinical Laboratory Science (ASCLS), as the preeminent organization for clinical laboratory science practitioners, provides dynamic leadership and vigorously promotes all aspects of clinical laboratory science practice, education and management to ensure excellent, accessible cost-effective laboratory services for the consumers of health care. We hope this website will be a useful and informative addition to your membership benefits

Core Values
  • Promoting the value of the profession to healthcare and the public; 
  • Uniting the profession to speak with one voice; Advocating on behalf of the profession; 
  • Promoting professional independence; 
  • Enhancing quality standards and patient safety; Ensuring workplace safety; 
  • Providing professional development opportunities; 
  • Promoting expanded roles and contributions of clinical laboratory professionals to the healthcare team; 
  • Increasing the diversity in the profession and expanding the voice and role of under-represented individuals and groups. 

Description

ASCLS-HAWAII is affiliated with the American Society for Clinical Laboratory Science (ASCLS). The ASCLS-HAWAII is a part of ASCLS Region X, which include Arizona, California, and Nevada's Societies for Clinical Laboratory Science. Within ASCLS-HAWAII, members are able to discuss local and statewide problems, compare and contrast issues, standards and methodologies of their respective laboratories, and stimulate local/regional interest in the profession. ASCLS-HAWAII produces a newsletter, Kokonut Wireless Nius, to facilitate communications among its members. Workshops and seminars are sponsored to provide continuing education. ASCLS-HAWAII also sponsors an annual continuing education meeting in October of each year. As required by the ASCLS Bylaws, an individual must hold membership at the state and national levels. It is this organizational structure that allows for appropriate channeling of local needs to the national level and national activities and programs back to the individual members.